Monitoring of hemostasis in cardiac surgical patients: Impact of point- of-care testing on blood loss and transfusion outcomes

Clinical Chemistry

Volumn 43, Issue 9, 1997, Pages 1684-1696

  Despotis, George J ^b   Joist, J Heinrich ^a   Goodnough, Lawrence T ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEEDING; BLOOD TRANSFUSION; CONFERENCE PAPER; HEMOSTASIS; HUMAN; PATIENT MONITORING; PERIOPERATIVE PERIOD; SURGICAL PATIENT;

EID: 0030846781     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/43.9.1684     Document Type: Conference Paper

References (153)

1. Hardy JF, Perrault J, Tremblay N, Robitaille D, Blain R, Carrier M. The stratification of cardiac surgical procedures according to use of blood products: a retrospective analysis of 1480 cases. Can J Anaesth 1991;38:511-7.
2. Despotis GJ, Santoro SA, Spitznagel E, Kater KM, Cox JL, Barnes P, et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994;107:271-9.
3. Khuri SF, Wolfe JA, Josa M, Axford TC, Szymanski I, Assousa S, et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 1992;104:94-107.
4. Despotis GJ, Filos KS, Zoys TN, Hogue CWJ, Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996;82:13-21.
5. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass [Review]. Blood 1990;76:1680-97.
6. Kalter RD, Saul CM, Wetstein L, Soriano C, Reiss RF. Cardiopulmonary bypass. Associated hemostatic abnormalities. J Thorac Cardiovasc Surg 1979;77:427-35.
7. Heimark RL, Kurachi K, Fujikawa K, Davie EW. Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature 1980;286:456-60.
8. Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheikh S, Hunt B, et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993;82:3350-7.
9. de Haan J, Boonstra PW, Monnink SH, Ebels T, van Oeveren W. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. Ann Thorac Surg 1995;59:901-7.
10. Holloway DS, Summaria L, Sandesara J, Vagher JP, Alexander JC, Caprini JA. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemostasis 1988;59:62-7.
11. Yoshihara H, Yamamoto T, Mihara H. Changes in coagulation and fibrinolysis occurring in dogs during hypothermia. Thromb Res 1985;37:503-12.
12. Tabuchi N, de Haan J, Boonstra PW, van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106:828-33.
13. Stibbe J, Kluft C, Brommer EJ, Gomes M, de Jong DS, Nauta J. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984;14:375-82.
14. Hirsh J, Heparin [Review]. N Engl J Med 1991;324:1565-74.
15. Khuri SF, Valeri CR, Loscalzo J, Weinstein MJ, Birjiniuk V, Healey NA, et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995;60:1008-14.
16. John LC, Rees GM, Kovacs IB. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg 1993;105:816-22.
17. Cobel-Geard RJ, Hassouna HI. Interaction of protamine sulfate with thrombin. Am J Hematol 1983;14:227-33.
18. Ereth MH, Klindworth JT, Campbell BA, Sill JC. Protamine attenuates agonist induced platelet signaling/adhesion molecule expression [Abstract]. Anesth Analg 1996;82:5.
19. Wachtfogel YT, Kucich U, Greenplate J, Gluszko P, Abrams W, Weinbaum G, et al. Human neutrophil degranulation during extracorporeal circulation. Blood 1987;69:324-30.
20. Boisclair MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1 + 2. Thromb Haemostasis 1993;70:253-8.
21. Slaughter TF, LeBleu TH, Douglas JM Jr, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994;80:520-6.
22. Gralnick HR, Fischer RD. The hemostatic response to open-heart operations. J Thorac Cardiovasc Surg 1971;61:909-15.
23. Harker LA, Malpass TW, Branson HE, Hessel EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56:824-34.
24. Milam JD, Austin SF, Martin RF, Keats AS, Cooley DA. Alteration of coagulation and selected clinical chemistry parameters in patients undergoing open heart surgery without transfusions. Am J Clin Pathol 1981;76:155-62.
25. Marder VJ, Feinstein DI, Francis CW, Colman RW. Consumptive thrombohemorrhagic disorders. In: Coleman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice, 3rd ed. Philadelphia: Lippincott, 1994: 1023-63.
26. Lu H, Soria C, Commin PL, Soria J, Piwnica A, Schumann F, et al. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemostasis 1991;66: 633-7.
27. Lu H, Soria C, Cramer EM, Soria J, Maclouf J, Perrot JY, et al. Temperature dependence of plasmin-induced activation or inhibition of human platelets. Blood 1991;77:996-1005.
28. Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood 1985;65:32-40.
29. Cramer EM, Lu H, Caen JP, Soria C, Berndt MC, Tenza D. Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation. Blood 1991;77:694-9.
30. Mammen EF, Koets MH, Washington BC, Wolk LW, Brown JM, Burdick M, et al. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemostasis 1985;11:281-92.
31. Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemostasis 1978;5:1-26.
32. Muller N, Popov-Cenic S, Buttner W, Kladetzky RG, Egil H. Studies of fibrinolytic and coagulation factors during open heart surgery. II. Postoperative bleeding tendency and changes in the coagulation system. Thromb Res 1975;7:589-8.
33. Brooks DH, Bahnson HT. An outbreak of hemorrhage following cardiopulmonary bypass. Epidemiologic studies. J Thorac Cardiovasc Surg 1972;63:449-52.
34. Ellison N, Jobes DR. Effective hemostasis in the cardiac surgical patient: current status. In: Ellison N, Jobes DR, eds. Effective hemostasis in cardiac surgery. Philadelphia: WB Saunders, 1988: 195-201.
35. Tanaka K, Takao M, Yada I, Yuasa H, Kusagawa M, Deguchi K. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 1989;3:181-8.
36. Czer LS. Mediastinal bleeding after cardiac surgery: etiologies, diagnostic considerations, and blood conservation methods [Review]. J Cardiothorac Anesth 1989;3:760-75.
37. Harker LA. Bleeding after cardiopulmonary bypass. N Engl J Med 1986;314:1446-8.
38. George JN, Shattil SJ. The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991;324:27-39.
39. George JN, Pickett EB, Saucerman S, McEver RP, Kunicki TJ, Kieffer N, et al. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 1986; 78:340-8.
40. Rinder CS, Mathew JP, Rinder HM, Bonan J, Ault KA, Smith BR. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology 1991;75:563-70.
41. Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991;75:388-93.
42. Beurling-Harbury C, Galvan CA. Acquired decrease in platelet secretory ADP associated with increased postoperative bleeding in post-cardiopulmonary bypass patients and in patients with severe valvular heart disease. Blood 1978;52:13-23.
43. Kestin AS, Valeri CR, Khuri SF, Loscalzo J, Ellis PA, MacGregor H, et al. The platelet function defect of cardiopulmonary bypass. Blood 1993;82:107-17.
44. Milam JD. Blood transfusion in heart surgery. Clin Lab Med 1982;2:65-85.
45. Edmunds LH Jr, Ellison N, Colman RW, Niewiarowski S, Rao AK, Addonizio VP Jr, et al. Platelet function during cardiac operation: comparison of membrane and bubble oxygenators. J Thorac Cardiovasc Surg 1982;83:805-12.
46. Dechavanne M, Ffrench M, Pages J, Ffrench P, Boukerche H, Bryon PA, et al. Significant reduction in the binding of a monoclonal antibody (LYP 18) directed against the IIb/IIIa glycoprotein complex to platelets of patients having undergone extracorporeal circulation. Thromb Haemostasis 1987;57:106-9.
47. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-97.
48. Verska JJ. Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis. Ann Thorac Surg 1977;24:170-3.
49. Guffin AV, Dunbar RW, Kaplan JA, Bland JW Jr. Successful use of a reduced dose of protamine after cardiopulmonary bypass. Anesth Analg 1976;55:110-3.
50. Vertrees RA, Engelman RM, Breyer RH, Johnson J, Auvil J, Rousou JA. Protamine-induced anticoagulation following coronary bypass [Abstract]. Proc Am Acad Cardiovasc Pert 1985;6:84-8.
51. Babka R, Colby C, El-Etr A, Pifarre R. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg 1977;73:780-2.
52. Roth JA, Cukingnan RA, Scott CR. Use of activated coagulation time to monitor heparin during cardiac surgery. Ann Thorac Surg 1979;28:69-72.
53. Papaconstantinou C, Radegran K. Use of the activated coagulation time in cardiac surgery. Effects on heparin-protamine dosages and bleeding. Scand J Thorac Cardiovasc Surg 1981;15:213-5.
54. Jumean HG, Sudah F. Monitoring of anticoagulant therapy during open-heart surgery in children with congenital heart disease. Acta Haematol 1983;70:392-5.
55. Niinikoski J, Laato M, Laaksonen V, Jalonen J, Inberg MV. Use of activated clotting time to monitor anticoagulation during cardiac surgery. Scand J Thorac Cardiovasc Surg 1984;18:57-61.
56. Lefemine AA, Lewis M. Activated clotting time for control of anticoagulation during surgery. Am Surg 1985;51:274-8.
57. Preiss DU, Schmidt-Bleibtreu H, Berguson P, Metz G. Blood transfusion requirements in coronary artery surgery with and without the activated clotting time (ACT) technique. Klin Wochenschr 1985;63:252-6.
58. Metz S, Keats AS. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg 1990;49:440-4.
59. Akl BF, Vargas GM, Neal J, Robillard J, Kelly P. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1980;79:97-102.
60. Jobes DR, Schwartz AJ, Ellison N, Andrews R, Ruffini RA, Ruffini JJ. Monitoring heparin anticoagulation and its neutralization. Ann Thorac Surg 1981;31:161-6.
61. Urban MK, Gordan M, Farrell DT, Shaffer WB. The management of anti-coagulation during cardiopulmonary bypass (CPB) [Abstract]. Anesthesiology 1991;75:A437.
62. Bowie JE, Kemma GD. Automated management of heparin anticoagulation in cardiovascular surgery [Abstract]. Proc Am Acad Cardiovasc Pert 1985;6:1-10.
63. Gravlee GP, Rogers AT, Dudas LM, Taylor R, Roy RC, Case LD, et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 1992;76:393-401.
64. Gravlee GP, Haddon WS, Rothberger HK, Mills SA, Rogers AT, Bean VE, et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg 1990;99: 518-27.
65. Jobes DR, Schaffer GW, Aitken GL. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995;110:36-45.
66. Akervall N, Fridh L, Schott H, Sollen C. Protamine dosage effects on complement and hemostasis. Proc Soc Cardiothorac Anesth 1992;268.
67. Stern MP, Shastri K, Raza S, Logue G. Complement activation during cardiopulmonary bypass: the relative role of classical and alternate pathways [Abstract]. Proc Soc Cardiovasc Anesth 1991; 189.
68. Moorman RM, Zapol WM, Lowenstein E. Neutralization of heparin anticoagulation. In: Gravlee GP, Davis RF, Utley JR, eds. Cardiopulmonary bypass: principles and practice. Baltimore: Williams & Wilkins, 1993:381-2.
69. Boldt J, Schindler E, Osmer C, Wittstock M, Stertmann WA, Hempelmann, et al. Influence of different anticoagulation regimens on platelet function during cardiac surgery. Br J Anaesth 1994;73:639-44.
70. Despotis GJ, Joist JH, Hogue CW, Alsoufiev A, Kater K, Goodnough LT, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation: a prospective, randomized evaluation in patients undergoing cardiac operations. J Thorac Cardiovasc Surg 1995;110:46-54.
71. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-82.
72. Despotis GJ, Joist JH, Joiner-Maier D, Alsoufiev AL, Triantafillou AN, Goodnough LT, et al. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements. Ann Thorac Surg 1995;59:106-11.
73. Hardy JF, Belisle S, Robitaille D, Perrault J, Roy M, Gragnon L. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg 1996;112:154-61.
74. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1995;58:799-805.
75. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
76. Tollefson FA, Fernandez F, Gauthier D, Buchanan MR. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate. Semin Thromb Hemostasis 1985;86:385-91.
77. Despotis GJ, Joist JH, Hogue CW, Alsoufiev A, Joiner-Maier D, Santoro SA, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemostasis 1996;76:902-8.
78. Fernandez F, N'guyen P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986;43:491-5.
79. Suzuki K, Nishioka J, Hashimoto S. Inhibition of factor VIII-associated platelet aggregation by heparin and dextran sulfate and its mechanism. Biochim Biophys Acta 1979;585:416-26.
80. Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991;87:1787-93.
81. Goodnough LT, Johnston MF, Toy PT. The variability of transfusion practice in coronary artery bypass surgery. Transfusion Medicine Academic Award Group. JAMA 1991;265:86-90.
82. Simon TL, Akl BF, Murphy W. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg 1984;37:359-64.
83. NIH. Consensus conference. Platelet transfusion therapy. JAMA 1987;257:1777-80.
84. NIH. Consensus conference. Fresh-frozen plasma. Indications and risks. JAMA 1985;253:551-3.
85. Gundry SR, Drongowski RA, Klein MD, Coran AG. Postoperative bleeding in cardiovascular surgery. Does heparin rebound really exist? Am Surg 1989;55:162-5.
86. Shanberge JN, Murato M, Quattrociocchi-Longe T, van Neste L. Heparin-protamine complexes in the production of heparin rebound and other complications of extracorporeal bypass procedures. Am J Clin Pathol 1987;87:210-7.
87. Pifarre R, Babka R, Sullivan HJ, Montoya A, Bakhos M, El-Etr A. Management of postoperative heparin rebound following cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981;81:378-81.
88. Gravlee GP, Case LD, Angert KC, Rogers AT, Miller GS. Variability of the activated coagulation time. Anesth Analg 1988;67:469-72.
89. Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 1997;11:24-8.
90. Murray D, Brosnahan B, Pinnell B, Olson J. Comparative sensitivity of in-vitro hemostatic tests to heparin [Abstract]. Anesthesiology 1992;77:153.
91. Baugh RF, Deemar KA, Zimmermann JJ. Heparinase in the activated clotting time assay: monitoring heparin-independent alterations in coagulation function. Anesth Analg 1992;74:201-5.
92. Tejidor L, Oman D, Zimmermann JJ, Russo A, Rose M, Borzhemskaya L, et al. Use of Dade Hepzyme to eliminate interference in coagulation testing [Abstract]. Thromb Haemostasis 1993;69: 866.
93. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Zimmermann JJ, et al. In vitro reversal of heparin effect with heparinase: evaluation with whole blood prothrombin time and activated partial thromboplastin time in cardiac surgical patients. Anesth Analg 1994;79:670-4.
94. Wang JS, Lin CY, Albertucci M, La Duca F, Pan C, Lee BK, et al. Identification of heparin rebound by measurement of whole blood thrombin time in CABG patients [Abstract]. Anesthesiology 1992; 77:144.
95. Jobes D, Aitken GL, Pan CM, La Duca F. Detection of residual heparin anticoagulation following cardiopulmonary bypass using a whole blood thrombin time assay [Abstract]. Thromb Haemostasis 1993;69:1110.
96. Traber KB, Jobes DR. Approach to the bleeding patient. In: Carol LL, Moore RA, eds. Blood: hemostasis, transfusion, and alternatives in the perioperative period. New York: Raven Press, 1995: 213-25.
97. Horrow JC. Management of coagulopathy associated with cardiopulmonary bypass. In: Gravlee GP, Davis RF, Utley JR, eds. Cardiopulmonary bypass: principles and practice. Baltimore: Williams & Wilkins, 1993:436-66.
98. Goodnough LT, Johnston MF, Ramsey G, Sayers MH, Eisenstadt RS, Anderson KC, et al. Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Transfusion Practices Committee of the American Association of Blood Banks. Ann Thorac Surg 1990;50:675-83.
99. Counts RB, Haisch C, Simon TL, Maxwell NG, Heimbach DM, Carrico CJ. Hemostasis in massively transfused trauma patients. Ann Surg 1979;190:91-9.
100. Gravlee GP, Hopkins MB. Blood plasma products. In: Ellison N, Jobes DR, eds. Effective hemostasis in cardiac surgery. Philadelphia: WB Saunders, 1988:75-6.
101. Ciavarella D, Reed RL, Counts RB, Baron L, Pavlin E, Heimbach DM, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 1987;67:365-8.
102. Despotis GJ, Grishaber JE, Goodnough LT. The effect of an intraoperative treatment algorithm on physicians' transfusion practice in cardiac surgery. Transfusion 1994;34:290-6.
103. Paone G, Spencer T, Silverman NA. Blood conservation in coronary artery surgery. Surgery 1994;116:672-7.
104. Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995;9:168-73.
105. Spiess BD. Coagulation dysfunction after cardiopulmonary bypass. In: Williams JP, ed. Postoperative management of the cardiac surgical patient. New York: Churchill Livingstone, 1996: 180-90.
106. Despotis GJ, Santoro SA, Spitznagel E, Kater KM, Barnes P, Cox JL, et al. On-site prothrombin time, activated partial thromboplastin time, and platelet count. A comparison between whole blood and laboratory assays with coagulation factor analysis in patients presenting for cardiac surgery. Anesthesiology 1994; 80:338-51.
107. Despotis GJ, Alsoufiev A, Hogue CW, Zoys TN, Goodnough LT, Santoro SA, et al. Comparison of CBC results from a new, on-site hemocytometer to a laboratory-based hemocytometer. Crit Care Med 1996;24:1163-7.
108. Lucas FV, Duncan A, Jay R, Coleman R, Craft P, Chan B, et al. A novel whole blood capillary technique for measuring the prothrombin time. Am J Clin Pathol 1987;88:442-6.
109. Ansell J, Tiarks C, Hirsh J, McGehee W, Adler D, Weibert R. Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood. A new method for monitoring heparin therapy. Am J Clin Pathol 1991;95:222-7.
110. Reich DL, Yanakakis MJ, Vela-Cantos FP, DePerio M, Jacobs E. Comparison of bedside coagulation monitoring tests with standard laboratory tests in patients after cardiac surgery. Anesth Analg 1993;77:673-9.
111. Nuttall GA, Oliver WC Jr, Beynen FM, Dull JJ, Murray MJ, Nichols WL. Intraoperative measurement of activated partial thromboplastin time and prothrombin time by a portable laser photometer in patients following cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993;7:402-9.
112. Naghibi F, Han Y, Dodds WJ, Lawrence CE. Effects of reagent and instrument on prothrombin times, activated partial thromboplastin times and patient/control ratios. Thromb Haemostasis 1988; 59:455-63.
113. Morrow JC, Malik N, Pan CM, Loder C, La Duca F. Fibrinogen measurement for hemostasis assessment during cardiac surgery [Abstract]. Thromb Haemostasis 1993;69:818.
114. Oberhardt BJ, Ernst PS, Alkadhi ZY. Measuring fibrinogen from finger stick samples using a dry chemistry based system [Abstract]. Thromb Haemostasis 1993;69:1082.
115. Sane DC, Gresalfi NJ, Enney-O'Mara LA, Califf RM, Greenberg CS, Bovill EG, et al. Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters during thrombolytic therapy. Blood Coagul Fibrinolysis 1992;3:47-54.
116. Dorman BH, Spinale FG, Bailey MK, Kratz JM, Roy RC. Identification of patients at risk for excessive blood loss during coronary artery bypass surgery: thromboelastography versus coagulation screen. Anesth Analg 1993;76:694-700.
117. Gravlee GP, Arora S, Lavender SW, Mills SA, Hudspeth AS, Cordell AR, et al. Predictive value of blood clotting tests in cardiac surgical patients. Ann Thorac Surg 1994;58:216-21.
118. Essell JH, Martin TJ, Salinas J, Thompson JM, Smith VC. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993;7:410-5.
119. Fassin W, Himpe D, Alexander JP, Borms S, Theunissen W, Muylaert P, et al. Predictive value of coagulation testing in cardiopulmonary bypass surgery. Acta Anaesthesiol Belg 1991; 42:191-8.
120. Despotis GJ, Filos K, Levine V, Goodnough LT, Santoro S. Evaluation of a new, point-of-care test that evaluates PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996;85:1311-23.
121. Gelb AB, Roth RI, Levin J, London MJ, Noall RA, Hauck WW, et al. Changes in blood coagulation during and following cardiopulmonary bypass: lack of correlation with clinical bleeding. Am J Clin Pathol 1996;106:87-99.
122. Uchiyama S, Stropp JQ, Claypool DA, Didisheim P, Dewanjee MK. Filter bleeding time: a new in vitro test of hemostasis. I. Evaluation in normal and thrombocytopenic subjects. Thromb Res 1983;31:99-115.
123. Kratzer MA, Born GV. Simulation of primary haemostasis in vitro. Haemostasis 1985;15:357-62.
124. Greilich PE, Carr ME Jr, Carr SL, Chang AS. Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage. Anesth Analg 1995;80:459-65.
125. Greilich PE, Carr ME, Zekert SL, Dent RM. Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease. Am J Med Sci 1994;307:15-20.
126. Tuman KJ, Spiess BD, McCarthy RJ, Ivankovich AD. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg 1989;69:69-75.
127. Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992;77:38-46.
128. Saleem A, Blifeld C, Saleh SA, Yawn DH, Mace ML, Schwartz M, et al. Viscoelastic measurement of clot formation: a new test of platelet function. Ann Clin Lab Sci 1983;13:115-24.
129. Coller BS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997;95:860-6.
130. Klindworth JT, MacVeigh I, Ereth MH. The platelet activated clotting test (PACT) predicts platelet dysfunction associated with cardiopulmonary bypass (CPB) [Abstract]. Anesth Analg 1996; 82:99-100.
131. Feldman MD, McCrae KR. Clinical coagulation laboratory evaluation of hemostasis in the perioperative period. In: Lake CL, Moore RA, eds. Blood: hemostasis, transfusion, and alternatives in the perioperative period. New York: Raven Press, 1995: 153-78.
132. Carr ME Jr, Carr SL. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects. Thromb Res 1994;75:617-30.
133. ™) on a new test of PAF procoagulant activity of whole blood. Thromb Res 1997;86:205-19.
134. Wang JS, Lin CY, Hung WT, O'Connor MF, Thisted RA, Lee BK, et al. Thromboelastogram fails to predict postoperative hemorrhage in cardiac patients. Ann Thorac Surg 1992;53:435-9.
135. Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilla A and von Willebrand's disease. Br J Haematol 1981;47:283-93.
136. Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983;308:8-12.
137. Burroughs AK, Matthews K, Qadiri M, Thomas N, Kernoff P, Tuddenham E, et al. Desmopressin and bleeding time in patients with cirrhosis. Br Med J 1985;291:1377-81.
138. Salzman EW, Weinstein MJ, Weintraub RM, Ware JA, Thurer RL, Robertson, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986;314:1402-6.
139. Dilthey G, Dietrich W, Spannagl M, Richter JA. Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J Cardiothorac Vasc Anesth 1993;7:425-30.
140. Hackmann T, Gascoyne RD, Naiman SC, Growe GH, Burchill LD, Jamieson WR, et al. A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med 1989;321:1437-43.
141. Mongan PD, Hosking MP. Desmopressin decreases blood loss and transfusion therapy after high risk CPB procedures [Abstract]. Anesth Analg 1994;78:292.
142. Beck KH, Bleckmann U, Mohr P, Kretschmer V. DDAVP's shortening of the bleeding time seems due to plasma von Willebrand factor. Semin Thromb Hemostasis 1995;21:40-3.
143. Lazenby WD, Russo I, Zadeh BJ, Zelano JA, Ko W, Lynch CC, et al. Treatment with desmopressin acetate in routine coronary artery bypass surgery to improve postoperative hemostasis. Circulation 1990;82:413-9.
144. Ghosh S, Rao AK. Lack of effect of 1-desamino-8-D-arginine vasopressin on direct adhesion of platelets to collagen. Thromb Res 1993;70:417-22.
145. Sloand EM, Alyono D, Klein HG, Chang P, Yu M, Lightfoot FG, et al. 1-Deamino-8-D-arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass. Am J Hematol 1994;46:199-207.
146. Horstman LL, Valle-Riestra BJ, Jy W, Wang F, Mao W, Ahn YS. Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity. Thromb Res 1995;79:163-74.
147. Lattuada A, Varanukulsak P, Castaman GC, Mannucci PM. The response of plasma von Willebrand factor to desmopressin (DDAVP) is related to the platelet levels of von Willebrand factor. Thromb Res 1992;67:467-71.
148. Kang Y, Lewis JH, Navalgund A, Russell MW, Bontempo FA, Niren LS, et al. ε-Aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987;66:766-73.
149. Spiess BD, Logas WG, Tuman KJ, Hughes T, Jagmin J, Ivankovich AD. Thromboelastography used for detection of perioperative fibrinolysis: a report of four cases. J Cardiothorac Vasc Anesth 1988;2:666-72.
150. Whitten CW, Allison PM, Latson TW, Elmore J, Gulden RH, Burkhardt B, et al. Thromboelastographic fibrinolysis does not correlate with levels of D-dimer after cardiopulmonary bypass [Abstract]. Anesthesiology 1991;75:A432.
151. John MA, Elms MJ, O'Reilly EJ, Rylatt DB, Bundesen PG, Hillyard CJ. The simpliRED D dimer test: a novel assay for the detection of crosslinked fibrin degradation products in whole blood. Thromb Res 1990;58:273-81.
152. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Panju A, van Beek EJ, et al. Application of a novel and rapid whole blood assay for D-dimer in patients with clinically suspected pulmonary embolism. Thromb Haemostasis 1995;73:35-8.
153. Wells PS, Brill-Edwards P, Stevens P, Panju A, Patel A, Douketis J, et al. A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. Circulation 1995;91:2184-7.